Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642902 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
A Phase 2 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
NCT00642902 is a Phase 2 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 255 participants.
The verdict
NCT00642902, a Phase 2 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces central nervous system inflammation in subjects with relapsing multiple sclerosis (RMS) as assessed by frequent magnetic resonance imaging (MRI). This study is randomised. Study medication is administered via subcutaneous (under the skin) injections.
Interventions
- DRUG Atacicept
- DRUG Placebo matched to atacicept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00642902
The ClinicalTrials.gov registry entry for NCT00642902 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atacicept is the first listed.
NCT00642902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00642902 about?
NCT00642902 is a clinical study titled "A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)". To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces central nervous system inflammation in subjects with relapsing multiple sclerosis (RMS) as assessed by frequent magnetic resonance imaging (MRI). This study is randomised. Study medication is administered via su...
What is the current status of trial NCT00642902?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2008-04. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00642902?
The interventions under investigation include: Atacicept (DRUG), Placebo matched to atacicept (DRUG).
Who is sponsoring clinical trial NCT00642902?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.